Ryan Joseph Sullivan, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanoma | 20 | 2014 | 5446 | 1.690 |
Why?
|
Proto-Oncogene Proteins B-raf | 10 | 2014 | 2015 | 1.340 |
Why?
|
Sarcoma, Kaposi | 8 | 2010 | 365 | 1.210 |
Why?
|
Herpesvirus 8, Human | 7 | 2010 | 258 | 1.200 |
Why?
|
Molecular Targeted Therapy | 5 | 2014 | 2727 | 0.840 |
Why?
|
Skin Neoplasms | 11 | 2014 | 5632 | 0.740 |
Why?
|
Protein Kinase Inhibitors | 6 | 2014 | 5502 | 0.500 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 3 | 2014 | 648 | 0.430 |
Why?
|
Interleukin-2 | 3 | 2014 | 1883 | 0.400 |
Why?
|
MAP Kinase Signaling System | 3 | 2013 | 1522 | 0.390 |
Why?
|
Biological Assay | 1 | 2014 | 653 | 0.370 |
Why?
|
Amino Acid Substitution | 2 | 2014 | 1793 | 0.350 |
Why?
|
Lymphoma, Primary Effusion | 1 | 2008 | 17 | 0.330 |
Why?
|
Oximes | 4 | 2014 | 309 | 0.330 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2014 | 1896 | 0.310 |
Why?
|
Antineoplastic Agents | 7 | 2014 | 13635 | 0.300 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 1431 | 0.300 |
Why?
|
Herpesviridae Infections | 1 | 2008 | 276 | 0.290 |
Why?
|
Anthracyclines | 1 | 2009 | 283 | 0.290 |
Why?
|
Indoles | 4 | 2014 | 1832 | 0.250 |
Why?
|
Immunotherapy | 4 | 2014 | 4391 | 0.250 |
Why?
|
Pyrimidinones | 4 | 2014 | 371 | 0.240 |
Why?
|
Imidazoles | 4 | 2014 | 1207 | 0.240 |
Why?
|
Antibodies, Monoclonal | 4 | 2014 | 9259 | 0.240 |
Why?
|
Signal Transduction | 7 | 2014 | 23355 | 0.230 |
Why?
|
Antiviral Agents | 3 | 2010 | 2971 | 0.220 |
Why?
|
Pyridones | 4 | 2014 | 707 | 0.210 |
Why?
|
Neoplasm Metastasis | 5 | 2014 | 4832 | 0.190 |
Why?
|
AIDS-Related Opportunistic Infections | 3 | 2010 | 664 | 0.190 |
Why?
|
Sulfonamides | 3 | 2014 | 1934 | 0.170 |
Why?
|
Immunologic Factors | 1 | 2009 | 1571 | 0.170 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2014 | 5148 | 0.160 |
Why?
|
Thoracic Injuries | 2 | 2011 | 270 | 0.150 |
Why?
|
Lymphoma, AIDS-Related | 2 | 2007 | 84 | 0.150 |
Why?
|
Neoplasm Staging | 8 | 2013 | 10961 | 0.140 |
Why?
|
HIV Infections | 4 | 2014 | 16764 | 0.130 |
Why?
|
Cytokines | 1 | 2010 | 7298 | 0.130 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 11410 | 0.110 |
Why?
|
Groin | 1 | 2013 | 102 | 0.110 |
Why?
|
Melanoma-Specific Antigens | 1 | 2013 | 80 | 0.110 |
Why?
|
Radiosurgery | 2 | 2013 | 1305 | 0.110 |
Why?
|
Brain Neoplasms | 1 | 2013 | 8791 | 0.100 |
Why?
|
Codon | 1 | 2014 | 613 | 0.100 |
Why?
|
Cell Line, Tumor | 5 | 2014 | 16646 | 0.100 |
Why?
|
Lymphatic Diseases | 1 | 2013 | 324 | 0.100 |
Why?
|
Cell Separation | 2 | 2014 | 1739 | 0.100 |
Why?
|
RNA, Neoplasm | 1 | 2014 | 761 | 0.100 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 364 | 0.100 |
Why?
|
Humans | 34 | 2014 | 739398 | 0.100 |
Why?
|
Uveal Neoplasms | 1 | 2013 | 310 | 0.090 |
Why?
|
DNA, Complementary | 1 | 2014 | 2049 | 0.090 |
Why?
|
Disease-Free Survival | 4 | 2013 | 6871 | 0.090 |
Why?
|
Aniline Compounds | 1 | 2014 | 990 | 0.090 |
Why?
|
Thoracotomy | 1 | 2011 | 365 | 0.090 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2011 | 358 | 0.080 |
Why?
|
Wounds, Penetrating | 1 | 2011 | 306 | 0.080 |
Why?
|
Genes, ras | 1 | 2012 | 693 | 0.080 |
Why?
|
Hemothorax | 1 | 2008 | 59 | 0.080 |
Why?
|
Empyema, Pleural | 1 | 2008 | 62 | 0.080 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2007 | 2241 | 0.080 |
Why?
|
Chest Tubes | 1 | 2008 | 149 | 0.080 |
Why?
|
Unnecessary Procedures | 1 | 2011 | 428 | 0.080 |
Why?
|
Pyrroles | 1 | 2014 | 1142 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2014 | 909 | 0.070 |
Why?
|
Clinical Trials as Topic | 4 | 2013 | 7897 | 0.070 |
Why?
|
Deoxycytidine | 1 | 2011 | 825 | 0.070 |
Why?
|
Mutation | 5 | 2014 | 29658 | 0.070 |
Why?
|
Immunosuppressive Agents | 2 | 2010 | 4143 | 0.070 |
Why?
|
Lymphocytes | 1 | 2014 | 2612 | 0.070 |
Why?
|
Lymphatic Metastasis | 1 | 2013 | 2897 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2014 | 3453 | 0.060 |
Why?
|
Liposomes | 1 | 2009 | 760 | 0.060 |
Why?
|
DNA Mutational Analysis | 2 | 2012 | 4182 | 0.060 |
Why?
|
Pericardial Effusion | 1 | 2007 | 241 | 0.060 |
Why?
|
Cell Transformation, Viral | 1 | 2006 | 565 | 0.060 |
Why?
|
Drugs, Investigational | 1 | 2007 | 215 | 0.060 |
Why?
|
Mutation, Missense | 1 | 2014 | 2552 | 0.060 |
Why?
|
Thoracic Surgery | 1 | 2011 | 715 | 0.060 |
Why?
|
Biopsy | 2 | 2013 | 6722 | 0.060 |
Why?
|
Models, Genetic | 1 | 2014 | 3493 | 0.060 |
Why?
|
Angiogenesis Inhibitors | 1 | 2014 | 2037 | 0.060 |
Why?
|
Immunocompromised Host | 1 | 2008 | 845 | 0.060 |
Why?
|
Aged | 10 | 2014 | 162698 | 0.060 |
Why?
|
Base Sequence | 1 | 2014 | 12804 | 0.050 |
Why?
|
Radiography | 1 | 2013 | 6998 | 0.050 |
Why?
|
Retrospective Studies | 8 | 2014 | 76631 | 0.050 |
Why?
|
Sequence Analysis, DNA | 1 | 2013 | 4791 | 0.050 |
Why?
|
Male | 16 | 2014 | 349022 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4555 | 0.050 |
Why?
|
Patient Selection | 1 | 2014 | 4211 | 0.050 |
Why?
|
Virus Replication | 1 | 2009 | 2529 | 0.050 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 18125 | 0.050 |
Why?
|
Tumor Microenvironment | 1 | 2013 | 3508 | 0.050 |
Why?
|
Adult | 12 | 2014 | 213394 | 0.040 |
Why?
|
Treatment Outcome | 4 | 2014 | 62693 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 12328 | 0.040 |
Why?
|
Protein Biosynthesis | 1 | 2006 | 2131 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2010 | 2220 | 0.040 |
Why?
|
Middle Aged | 10 | 2014 | 212863 | 0.040 |
Why?
|
Head and Neck Neoplasms | 1 | 2011 | 2706 | 0.040 |
Why?
|
Prognosis | 5 | 2013 | 28901 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 4743 | 0.030 |
Why?
|
Disease Progression | 1 | 2010 | 13237 | 0.030 |
Why?
|
Female | 11 | 2014 | 378853 | 0.030 |
Why?
|
raf Kinases | 1 | 2013 | 122 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 2011 | 5213 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2014 | 17384 | 0.030 |
Why?
|
Ritonavir | 1 | 2014 | 324 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2011 | 7626 | 0.030 |
Why?
|
CA-19-9 Antigen | 1 | 2011 | 110 | 0.020 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2013 | 338 | 0.020 |
Why?
|
Biomarkers, Pharmacological | 1 | 2012 | 163 | 0.020 |
Why?
|
Chicago | 1 | 2011 | 237 | 0.020 |
Why?
|
Melanoma, Experimental | 1 | 2014 | 562 | 0.020 |
Why?
|
HT29 Cells | 1 | 2010 | 200 | 0.020 |
Why?
|
Mice | 2 | 2014 | 81002 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2011 | 589 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2010 | 295 | 0.020 |
Why?
|
Mucous Membrane | 1 | 2013 | 667 | 0.020 |
Why?
|
Tamoxifen | 1 | 2014 | 978 | 0.020 |
Why?
|
Drug Interactions | 1 | 2014 | 1456 | 0.020 |
Why?
|
Survival Analysis | 2 | 2013 | 10247 | 0.020 |
Why?
|
Valine | 1 | 2010 | 413 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2011 | 982 | 0.020 |
Why?
|
Blood Chemical Analysis | 1 | 2010 | 441 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2013 | 1285 | 0.020 |
Why?
|
Multiple Trauma | 1 | 2011 | 366 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2013 | 2503 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2011 | 20055 | 0.020 |
Why?
|
PTEN Phosphohydrolase | 1 | 2014 | 1142 | 0.020 |
Why?
|
Thoracostomy | 1 | 2008 | 72 | 0.020 |
Why?
|
Cost-Benefit Analysis | 2 | 2011 | 5462 | 0.020 |
Why?
|
Survival Rate | 2 | 2013 | 12761 | 0.020 |
Why?
|
Injury Severity Score | 1 | 2011 | 1011 | 0.020 |
Why?
|
Universities | 1 | 2013 | 946 | 0.020 |
Why?
|
Neurologic Examination | 1 | 2011 | 932 | 0.020 |
Why?
|
Thoracoscopy | 1 | 2008 | 178 | 0.020 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2014 | 827 | 0.020 |
Why?
|
Aged, 80 and over | 4 | 2013 | 57650 | 0.020 |
Why?
|
Animals | 3 | 2014 | 168368 | 0.020 |
Why?
|
Trauma Severity Indices | 1 | 2008 | 480 | 0.020 |
Why?
|
Brain | 1 | 2013 | 26345 | 0.020 |
Why?
|
Trauma Centers | 1 | 2011 | 888 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2014 | 1994 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2014 | 1497 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2013 | 1977 | 0.020 |
Why?
|
Blotting, Western | 1 | 2013 | 5181 | 0.020 |
Why?
|
Hospital Costs | 1 | 2011 | 982 | 0.020 |
Why?
|
Glutamic Acid | 1 | 2010 | 1168 | 0.020 |
Why?
|
Neoplasms | 1 | 2014 | 21507 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2011 | 2872 | 0.020 |
Why?
|
Matrix Metalloproteinases | 1 | 2006 | 391 | 0.020 |
Why?
|
Receptors, Chemokine | 1 | 2006 | 669 | 0.010 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2011 | 967 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2011 | 4935 | 0.010 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 1625 | 0.010 |
Why?
|
Drainage | 1 | 2007 | 1139 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2011 | 2261 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2011 | 6516 | 0.010 |
Why?
|
HIV-1 | 2 | 2008 | 6931 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2013 | 38942 | 0.010 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2006 | 1675 | 0.010 |
Why?
|
Viral Proteins | 1 | 2006 | 1900 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2011 | 8605 | 0.010 |
Why?
|
Boston | 1 | 2011 | 9314 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2013 | 13002 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2011 | 5305 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2013 | 10455 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2006 | 3194 | 0.010 |
Why?
|
Apoptosis | 1 | 2013 | 9714 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2006 | 2639 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2014 | 21863 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2007 | 3454 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2006 | 3802 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2011 | 15036 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 14740 | 0.010 |
Why?
|
Young Adult | 2 | 2011 | 56255 | 0.010 |
Why?
|
Ultrasonography | 1 | 2007 | 5941 | 0.010 |
Why?
|
Models, Biological | 1 | 2010 | 9609 | 0.010 |
Why?
|
Adolescent | 2 | 2012 | 85405 | 0.010 |
Why?
|
Risk Factors | 2 | 2011 | 71974 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2010 | 9122 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2007 | 12948 | 0.010 |
Why?
|
Algorithms | 1 | 2011 | 13872 | 0.010 |
Why?
|
Risk Assessment | 1 | 2011 | 23294 | 0.010 |
Why?
|
Time Factors | 1 | 2011 | 40050 | 0.010 |
Why?
|